Acoramidis
Amyloidogenic Transthyretin (ATTR) Amyloidosis
Eidos Therapeutics, a BridgeBio companySmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Amyloidogenic Transthyretin (ATTR) Amyloidosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
prx004 Prothena Biosciences Limited | Phase 1 | CC |
EVUZAMITIDE Lorena Saelices | D |
Same molecule, other indications
Acoramidis is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →